Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Diagnosis of RA ≥6 months duration, according to the ACR /European League against Rheumatism (EULAR) 2010 RA Classification Criteria~ACR Class I-III functional status, based on 1991 revised criteria~Anti-TNF therapy failures, defined by the investigator as participants with an inadequate clinical response, after being treated for at least 3 consecutive months, and/or intolerance to at least 1 anti-TNF blocker(s), resulting in or requiring their discontinuation:~* TNF-blockers included, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab~Moderate-to-severely active RA~Continuous treatment with one or a combination of DMARDs (except for simultaneous combination use of leflunomide and methotrexate) for at least 12 weeks prior to baseline and on a stable dose(s) for at least 6 weeks prior to screening:~* Methotrexate - 6 to 25 mg/week orally or parenterally~* Leflunomide - 10 to 20 mg orally daily~* Sulfasalazine - 1000 to 3000 mg orally daily~* Hydroxychloroquine - 200 to 400 mg orally daily~Exclusion criteria:~Participants \<18 years of age or legal adult age~Past history of, or current, autoimmune or inflammatory systemic or localized joint disease(s) other than RA~History of juvenile idiopathic arthritis or arthritis onset prior to age 16~Severe active systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome.~Treatment with anti-TNF agents, as follows:~* Within 28 days prior to the baseline visit - etanercept~* Within 42 days prior to the baseline visit - infliximab, adalimumab, golimumab, certolizumab pegol~Treatment with previous RA-directed biologic agents with other than TNF antagonist mechanisms:~Within 28 days prior to the randomization (baseline) visit - anakinra Within 42 days prior to the randomization (baseline) visit - abatacept~Within 6 months prior to the randomization (baseline) visit - any cell depleting agents including but not limited to rituximab without a normal lymphocyte and cluster of differentiation (CD) 19+ lymphocyte count~Treatment with any DMARD other than those allowed per protocol and limited to the maximum specified dosage within 12 weeks prior to baseline~Treatment with prednisone \>10 mg or equivalent per day, or change in dosage within 4 weeks prior to baseline visit~Any parenteral or intra-articular glucocorticoid injection within 4 weeks prior to baseline~Prior treatment with anti-interleukin (IL) -6 or IL-6 receptor antagonist therapies, including tocilizumab or sarilumab, participation in a prior study of sarilumab, irrespective of treatment arm~Prior treatment with a Janus kinase inhibitor (such as tofacitinib)~New treatment or dose-adjustment to ongoing medication for dyslipidemia within 6 weeks prior to randomization, ie, stable dose for at least 6 weeks prior to randomization~Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first investigational medicinal product (IMP) administration, whichever was longer~History of alcohol or drug abuse within 5 years prior to the screening visit~Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit. Nonmalignant lymphoproliferative disorders were also excluded~Participants with active tuberculosis or latent tuberculosis infection~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo q2w (Type: PLACEBO_COMPARATOR): Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
- Sarilumab 150 mg q2w (Type: EXPERIMENTAL): Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
- Sarilumab 200 mg q2w (Type: EXPERIMENTAL): Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).